SARS‐CoV‐2 research using human pluripotent stem cells and organoids

Sayaka Deguchi; Ángel Serrano‐aroca; Murtaza M. Tambuwala; Bruce D. Uhal; Adam M. Brufsky; Kazuo Takayama

doi:10.1002/sctm.21-0183

SARS‐CoV‐2 research using human pluripotent stem cells and organoids

Sayaka Deguchi
, Ángel Serrano‐aroca
, Murtaza M. Tambuwala
, Bruce D. Uhal
, Adam M. Brufsky
, Kazuo Takayama

Michigan State University

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

68 Downloads (Pure)

Abstract

Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

Original language	English
Pages (from-to)	1491-1499
Number of pages	9
Journal	STEM CELLS Translational Medicine
Volume	10
Issue number	11
DOIs	https://doi.org/10.1002/sctm.21-0183
Publication status	Published (in print/issue) - 24 Jul 2021

Bibliographical note

Funding Information:
We thank Dr. Peter Karagiannis (Kyoto University) for critical reading of the manuscript and Dr. Misaki Ouchida (Kyoto University) for drawing the graphical abstract.

Publisher Copyright:
© 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.

Funding

Funding Information: We thank Dr. Peter Karagiannis (Kyoto University) for critical reading of the manuscript and Dr. Misaki Ouchida (Kyoto University) for drawing the graphical abstract. Publisher Copyright: © 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
SARS-CoV-2
human ES cells
human iPS cells
organoids

Access to Document

10.1002/sctm.21-0183Licence: CC BY-NC

sctm.21-0183 (1)Final published version, 456 KB

https://pubmed.ncbi.nlm.nih.gov/34302450/

Cite this

@article{00f0b89550a741baa1c2faa477cd9d68,

title = "SARS‐CoV‐2 research using human pluripotent stem cells and organoids",

abstract = "Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.",

keywords = "COVID-19, SARS-CoV-2, human ES cells, human iPS cells, organoids",

author = "Sayaka Deguchi and {\'A}ngel Serrano‐aroca and Tambuwala, \{Murtaza M.\} and Uhal, \{Bruce D.\} and Brufsky, \{Adam M.\} and Kazuo Takayama",

note = "Funding Information: We thank Dr. Peter Karagiannis (Kyoto University) for critical reading of the manuscript and Dr. Misaki Ouchida (Kyoto University) for drawing the graphical abstract. Publisher Copyright: {\textcopyright} 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.",

year = "2021",

month = jul,

day = "24",

doi = "10.1002/sctm.21-0183",

language = "English",

volume = "10",

pages = "1491--1499",

journal = "STEM CELLS Translational Medicine",

issn = "2157-6564",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - SARS‐CoV‐2 research using human pluripotent stem cells and organoids

AU - Deguchi, Sayaka

AU - Serrano‐aroca, Ángel

AU - Tambuwala, Murtaza M.

AU - Uhal, Bruce D.

AU - Brufsky, Adam M.

AU - Takayama, Kazuo

N1 - Funding Information: We thank Dr. Peter Karagiannis (Kyoto University) for critical reading of the manuscript and Dr. Misaki Ouchida (Kyoto University) for drawing the graphical abstract. Publisher Copyright: © 2021 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.

PY - 2021/7/24

Y1 - 2021/7/24

N2 - Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

AB - Experimental cell models are indispensable for clarifying the pathophysiology of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and for developing therapeutic agents. To recapitulate the symptoms and drug response of COVID-19 patients in vitro, SARS-CoV-2 studies using physiologically relevant human embryonic stem (ES)/induced pluripotent stem (iPS) cell-derived somatic cells and organoids are ongoing. These cells and organoids have been used to show that SARS-CoV-2 can infect and damage various organs including the lung, heart, brain, intestinal tract, kidney, and pancreas. They are also being used to develop COVID-19 therapeutic agents, including evaluation of their antiviral efficacy and safety. The relationship between COVID-19 aggravation and human genetic backgrounds has been investigated using genetically modified ES/iPS cells and patient-derived iPS cells. This review summarizes the latest results and issues of SARS-CoV-2 research using human ES/iPS cell-derived somatic cells and organoids.

KW - COVID-19

KW - SARS-CoV-2

KW - human ES cells

KW - human iPS cells

KW - organoids

UR - https://onlinelibrary.wiley.com/doi/10.1002/sctm.21-0183

UR - https://www.scopus.com/pages/publications/85111403074

U2 - 10.1002/sctm.21-0183

DO - 10.1002/sctm.21-0183

M3 - Article

C2 - 34302450

SN - 2157-6564

VL - 10

SP - 1491

EP - 1499

JO - STEM CELLS Translational Medicine

JF - STEM CELLS Translational Medicine

IS - 11

ER -

SARS‐CoV‐2 research using human pluripotent stem cells and organoids

Abstract

Bibliographical note

Funding

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this